2 unknown. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
| Phase 2 | 2 | Unknown 2 |
Follow Relapse Leukemia: new trials by email Literature Review of Relapse Leukemia trials Research Report on Relapse Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Allogeneic CD19 CAR-T cells - Relapse Leukemia, Refractory Leukemia | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2021-02-05 | 2021-12-20 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) GLIDE - Hematologic Cancer, Relapse Leukemia | Phase 1 / Phase 2 | Unknown | Ciusss de L'Est de l'Île de Montréal | 20 | 2017-02-06 | 2017-12-06 |
Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Cardiovascular Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1)
Ciusss de L'Est de l'Île de Montréal (1) · Shenzhen University General Hospital (1)
Canada (1) · China (1)
Denis-Claude Roy, MD PhD (1) · Li Yu, Dr (1) · Silvy Lachance, MD (1)